Adaptive Treatment of Metastatic Prostate Cancer Using Generative Artificial Intelligence.
Despite the expanding therapeutic options available to cancer patients, therapeutic resistance, disease recurrence, and metastasis persist as hallmark challenges in the treatment of cancer. The rise to prominence of generative artificial intelligence (GenAI) in many realms of human activities is com...
| Publicado en: | Clinical Medicine Insights: Oncology pp. 1 - 9 |
|---|---|
| Autor principal: | |
| Formato: | tables/charts Journal Article |
| Publicado: |
Sage Publications Inc.
01/6/2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=182074873&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 182074873 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11795549 B3KT jtl: Clinical Medicine Insights: Oncology issn: 11795549 maglogo: Y pubinfo: dt: 01/6/2025 pid: 344 pub: Sage Publications Inc. place: Thousand Oaks, California artinfo: ui: 182074873 182074873 182074873 10.1177/11795549241311408 182074873 ppf: 1 ppct: 8 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Adaptive Treatment of Metastatic Prostate Cancer Using Generative Artificial Intelligence. aug: au: Derbal, Youcef affil: Ted Rogers School of Information Technology Management, Toronto Metropolitan University, Toronto, ON, Canada sug: subj: Prostatic Neoplasms Drug Therapy Neoplasm Metastasis Drug Therapy Drug Therapy, Computer Assisted Artificial Intelligence, Generative Neoplastic Processes Chemotherapy, Cancer Androgen Antagonists Therapeutic Use ab: Despite the expanding therapeutic options available to cancer patients, therapeutic resistance, disease recurrence, and metastasis persist as hallmark challenges in the treatment of cancer. The rise to prominence of generative artificial intelligence (GenAI) in many realms of human activities is compelling the consideration of its capabilities as a potential lever to advance the development of effective cancer treatments. This article presents a hypothetical case study on the application of generative pre-trained transformers (GPTs) to the treatment of metastatic prostate cancer (mPC). The case explores the design of GPT-supported adaptive intermittent therapy for mPC. Testosterone and prostate-specific antigen (PSA) are assumed to be repeatedly monitored while treatment may involve a combination of androgen deprivation therapy (ADT), androgen receptor-signalling inhibitors (ARSI), chemotherapy, and radiotherapy. The analysis covers various questions relevant to the configuration, training, and inferencing of GPTs for the case of mPC treatment with a particular attention to risk mitigation regarding the hallucination problem and its implications to clinical integration of GenAI technologies. The case study provides elements of an actionable pathway to the realization of GenAI-assisted adaptive treatment of metastatic prostate cancer. As such, the study is expected to help facilitate the design of clinical trials of GenAI-supported cancer treatments. pubtype: Academic Journal doctype: tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|